TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Whole Eye Optical Coherence Tomography (OCT) to Improve Refractive Surgery and Eye Care

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 years or older.~* Pseudophakic group: has had prior uncomplicated cataract surgery with a monofocal or toric intraocular lens, able to undergo head MRI~* High myopia group: refraction equal to or stronger than -6 D spherical equivalent, able to undergo head MRI~Exclusion Criteria:~* under 21 years of age, unable or unwilling to give consent.~* Pseudophakic group: complications with cataract surgery or insertion of a multifocal intraocular lens, failure to pass MRI pre-screening (e.g. prior metallic implants, claustrophobic), unable to fixate.~* High myopia group: failure to pass MRI pre-screening, unable to fixate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Normals (Type: EXPERIMENTAL): Normal subjects will be imaged with the OCT system to ensure the imaging range of the system.
- Patients with a history of cataract surgery or high myopia (Type: EXPERIMENTAL): Subjects will be imaged with both the OCT system and MRI. Reconstructions of the eye from each modality will then be compared.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects~* Age 18-60~Exclusion Criteria:~* Primary psychiatric disease (DSM IV Axis I or WHO ICD-10 diagnostic classification).~* Present or former neurological diseases,~* Severe somatic disease~* Medication that can interfere with the test results.~* Doesn't speak Danish fluently or is severely, visually or hearing impaired.~* Information regarding former learning disabilities.~* Pregnancy at the time of the scanning~* Breast feeding~* MR-scanner incompatibility (metal in soft tissue)~* Alcohol or drug abuse~* Allergy to ingredients in used drugs~* Participation in experiments with radioactivity (\>10 mSv) within the last year or considerable work-related exposure to radioactivity.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Sumatriptan (Type: EXPERIMENTAL): In the pilot study (an MR-only study) subjects will receive up to five doses of sumatriptan in the range of 10 ug/kg to 80 ug/kg. This allows us to establish a dose-response curve for each subject. Administration of sumatriptan in the pilot study will be spaced with approximately one week apart to avoid carry-over effects of the drug.~In the main study (a PET-MR study), the sumatriptan dose with the maximal effect size and minimum side effects will be used for all subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Novel Interventions in HIV-1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented HIV-1 positive result.~* Stable on HAART.~* Two screening viral loads of \<50 cps/ml on 2 consecutive occasions at least one month apart.~* CD4 T cell count of \>400 cells/ul.~* Nadir CD4 T cell count of \>200 cells/ul.~* Over 18 years of age.~* Willing and able to provide informed consent.~* Female subjects must not be pregnant or lactating.~* Subjects must be using adequate double barrier method of contraception as appropriate.~Exclusion Criteria:~* Prior therapeutic vaccination.~* Acute illness within 2 weeks of the start of the study.~* Prior immunomodulatory therapy (e.g. IL-2, rhGH, GCSF, GM-CSF, HU)~* Receiving immunosuppressive medication (e.g. Steroids)~* Participation in other vaccine trials currently~* Patients with diabetes mellitus type 2~* Patients with cardiac abnormalities~* Patients with pre-existing autoimmune disease~* Patients with active neoplasia~* Patients with evidence of any progression or recurrence of an underlying intra-cranial lesion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Vaccine and cytokines (Type: EXPERIMENTAL): Day 0: Patients receive GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injection.~Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.~Further vaccine boosters are given on day 42 and day 84. GTU-MultiHIV B clade vaccine 1mg/ml being administered as 10 intradermal injections of 100 µl/injection.
- Vaccine alone (Type: ACTIVE_COMPARATOR): Day 0: Patients are given GTU-MultiHIV B clade vaccine 1mg/ml administered as 10 intradermal injections of 100 µl/injections.~Day 42: GTU-MultiHIV B clade vaccine as day 0.~Day 84: GTU-MultiHIV B clade vaccine as day 0.
- Cytokines alone (Type: ACTIVE_COMPARATOR): Day 7-11: One week following this, patients receive a 5 day course of Cytokines: Aldesleukin (IL-2) Novartis UK (BD; 8 hours apart) 5 million units administered by SC injection. Sargramostim (GM-CSF) - Leukine™, Berlex Seattle US 150ug SC once daily 4 hours from rhIL-2 injections.~Day 14-18: The following week, patients rhGH (Saizen™, Serono International, Geneva, Switzerland) 4mg/day self-administered SC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of 18F-FLT in Pediatric Patients With Central Nervous System (CNS) Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients with newly diagnosed central nervous system tumors undergoing planned surgical resection within 21 days.~* Patients should be \< 21 years of age at the time of diagnosis.~* Patients should be capable of achieving imaging without the need for sedation or anesthesia.~* Karnofsky Performance Status ≥ 50. For infants, the Lansky play scale ≥ 50% can be substituted.~* Patients must not be pregnant or nursing.~* Signed Informed Consent.~* Patients receiving steroids and/or anti-seizure medications are eligible for this study.~Exclusion Criteria:~* Prior radiation therapy and/or chemotherapy are not permitted.~* Active infection~* Pregnancy or breast feeding~* Serious concurrent medical illness

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- 18F-FLT (Type: EXPERIMENTAL): All subjects will receive 18F-FLT prior to PET imaging.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Primary Care-Based Physical Activity for Diabetic Latinas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have received a physician's diagnosis of type II diabetes and are currently being seen by a primary care physician~* Currently inactive, defined as participating in at least moderate intensity physical activity for less than 60 minutes per week~Exclusion Criteria:~* Medical condition that may make exercise unsafe, including congestive heart failure, severe musculoskeletal problems or pulmonary conditions, or other conditions determined by the referring physician to preclude unsupervised exercise~* Unable to receive mailed materials (do not have a mailing address)~* Unable to engage in physical activity for at least 30 minutes~* Have a current or planned pregnancy~* Planning to move from the area within the next year

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Tailored Physical Activity Intervention (Type: EXPERIMENTAL): Intervention group will receive Spanish-language physical activity print intervention based on SCT and Transtheoretical Model, (TTM) that emphasizes behavioral strategies for increasing activity levels.
- Standard of Care Control Group (Type: ACTIVE_COMPARATOR): Control group will receive standard of care through the Family Medicine clinic as well as monthly questionnaires on topics other than physical activity (e.g. diet) to complete.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Secretin Enhanced MRCP for Evaluation of Pancreatic Duct in Pediatric Population

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females 2-18 years of age~* Is clinically indicated for MRCP of the pancreas based on clinical criteria~* Scheduled for MRCP and therapeutic or diagnostic ERCP or surgery for the assessment of chronic pancreatitis or acute recurrent pancreatitis (Children with a single episode of pancreatitis will not be included)~* Parent or legal guardian has been fully informed and has personally signed and dated the Written Informed Consent and Health Insurance Portability Accountability Act (HIPAA) provisions~* Is a male, or is a female not of childbearing potential, or is a female of childbearing potential who is using effective contraception and has a negative serum pregnancy test on the same day, but prior to, study drug administration~* Is able and willing to complete all study procedures specified in the protocol~Exclusion Criteria:~* Presence of a pancreatic stent~* History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease which, in the opinion of the investigator, precludes study participation~* History of sensitivity to any of the ingredients in the study drug~* Pregnancy~* Any contraindication to MRI procedure, including but not limited to implanted metal devices (e.g., pacemaker, aneurysm clips, cochlear implants)

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Drug + MR with MRCP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In line with the diagnosis of uterine fibroids;~* With fibroids associated with clinical symptoms (such as uterine bleeding symptoms, symptoms of oppression, pain symptoms, etc.); or nearly 3 months fibroids gradually grow; or the largest fibroid diameter ≥ 5cm;~* Women of childbearing age over 18 years of age;~* Voluntarily tested and signed informed consent~Exclusion Criteria:~* Unexplained or vaginal bleeding other than uterine fibroids;~* Combined with malignant tumors (including reproductive and other systems), or endometrial ≥ 17mm;~* Is the use of simple progesterone contraceptives, progesterone-containing intrauterine device or compound oral contraceptives;~* Is using ketoconazole, itraconazole, erythromycin, rifampicin, adrenocorticotropic hormone (hydrocortisone, prednisone, dexamethasone, etc.), and some anticonvulsants (phenytoin, Phenobarbital, carbamazepine), griseofulvin, nonsteroidal antiinflammatory drugs (aspirin, acetaminophen, ibuprofen, etc.) and can not be discontinued during the study;~* Pregnant women and lactating women and medication or medication within 3 months after the cessation of births;~* Severe heart, liver, kidney disease and adrenal insufficiency, and / or ALT, AST\> 1.5 times the upper limit of normal, Cr\> normal upper limit;~* Allergies or previous allergy to a variety of drugs, or the study of active ingredients in the medication or any excipient allergy;~* Patients who have participated in other clinical trials within 3 months;~* Other investigators who are not considered to be involved in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mifepristone A group (Type: EXPERIMENTAL): Mifepristone tablets for 12 weeks with two follow-up
- Mifepristone B group (Type: EXPERIMENTAL): Mifepristone tablets for 12 weeks with four follow-up
- Mifepristone C group (Type: EXPERIMENTAL): Mifepristone tablets for 24 weeks with four follow-up

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women aged 18 to 36~2. BMI \> 19 \& \< 40~3. PCOS diagnosis as evidenced by:~Oligo- and/or anovulation (\< 6 cycles per year) and one of the following:~* Clinical and/or biochemical signs of hyperandrogenism~* Polycystic ovaries and exclusion of other aetiologies (congenital adrenal hyperplasias, androgen-secreting tumors, Cushing's syndrome)~Exclusion Criteria:~1. Use of ovulation induction agents within the past 6 months~2. Positive pregnancy test before taking study medications~3. History or current thromboembolic disorder~4. Coronary artery disease such as heart attack or stroke~5. Tobacco use or history within the past 6 months~6. History of pelvic inflammatory disease and tubal factor infertility~7. Congenital adrenal hyperplasia~8. Diabetes Mellitus~   * Any subject on Metformin must wash out for 30 days prior to screening~9. History of endometriosis~10. Known male factor infertility

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- Raloxifene (Type: EXPERIMENTAL): 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7
- Clomiphene (Type: ACTIVE_COMPARATOR): 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Airway Gene Expression in COPD and Controlled Populations

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 45-70 yrs of age, incl, women as described above as far as child-bearing potential and subjects who if they have coexisting disease, the disease is stable and does not place an untoward risk or result in compromise of data.~* Non smokers will be lifelong and have not worked in a chronic dusty environment.~* Smokers will require a minimum of 10 pkyr history and currently smoking at least a pack per day. The smokers without symptoms of COPD must demonstrate a pulmonary function with an FEV1 \> 80%. The FEV1/FVC ratio may be less than .7 however they can not demonstrate symptoms of chronic bronchitis by medical history. Smokers with symptoms must demonstrate an FEV1 \< 80% and FEV1/FVC \<.7.~Exclusion Criteria:~* Any female subject who is pregnant or breast-feeding or a female subject who is of child-bearing potential who is unwilling to sue two acceptable methods of birth control.~* Any condition that would place the subject at risk for endobronchial brushings(such as bleeding diathesis) or subjects who are currently taking anticoagulants.~* Any subject who has had an exacerbation of COPD within the last six months of screening or who has been hospitalized for any reason within the last three months.~* Illicit substances indicated by positive urine drug screen.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- methodologies to identify characteristics of non-smokers with normal lung function (Type: None): Imaging, genomic and proteomic methodologies to identify characteristics of individuals with normal lung function who do not smoke
- methodologies to identify characteristics of smokers but do not demonstrate symptoms of COPD (Type: None): Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke but who do not demonstrate symptoms of chronic obstructive pulmonary disease
- methodologies to identify characteristics of smokers that demonstrate symptoms of COPD (Type: None): Imaging, genomic and proteomic methodologies to identify characteristics of individuals who smoke that demonstrate symptoms of COPD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. HFrEF or HFmrEF, and ICD±CRT therapy \> 3 months~2. at least 10 documented VT episodes (either nsVT or sVT ± ICD treatment) within the last 12 months plus:~   * nt-proBNP \> 500pg/mL or~  * Left-ventricular Ejection Fraction (LV-EF) \< 35% or~  * hospitalization for heart failure within the last 12 months or~  * \> 100 nsVTs within the last 12 months~  * \> 1 sVT/VF within the last 12 months~3. Informed consent has to be given in written form.~4. estimated glomerular filtration rate (eGFR) \> 30 ml/min/1.73m2~5. Blood pressure before first drug dosing: blood pressure systolic \> 100 mmHg~6. Blood pressure before first drug dosing: blood pressure diastolic \> 60 mmHg~Exclusion Criteria:~1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis~2. Ongoing ventricular arrhythmia~3. Known allergy to SGLT-2 inhibitors~4. Haemodynamic instability as defined by intravenous administration of catecholamine, calciumsensitizers or phosphodiesterase inhibitors~5. \>1 episode of severe hypoglycemia within the last 6 months under treatment with insulin or sulfonylurea~6. Planned catheter ablation for ventricular arrhythmia~7. Planned explantation of ICD, or planned up/downgrade to/from CRT-D device~8. Existing therapy with SGLT-2 inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin (Type: ACTIVE_COMPARATOR): The subject will receive Ertugliflozin 5mg.
- Placebo (Type: PLACEBO_COMPARATOR): The subject will receive Placebo 5mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent~* Age \>18 years~* Histologically confirmed and centrally reviewed prostate adenocarcinoma based~* PSA within 60 days~* High risk prostate cancer defined as any one of: clinical stage \>= T3, Gleason score \>= 8, or PSA \>=20 and \<50 ng/mL.~Exclusion Criteria:~* Evidence of lymph node metastasis~* Evidence of distant metastases~* Prior pelvic radiotherapy or brachytherapy~* Previous radical prostatectomy, cryotherapy, or high-frequency ultrasound~* Unable to undergo gold seed insertion~* Immunosuppressive medications~* Inflammatory bowel disease~* Unable to undergo MRI~* Previous bilateral orchiectomy~* Previous hormonal therapy including LHRH agonists (leuprolide, goserelin), LHRH antagonists (degarelix), anti-androgens (bicalutamide, flutamide, nilutamide), surgical castration, and estrogens~* Previous finasteride within 14 days.~* Previous dutasteride within 180 days.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Prostate stereotactic body RT with MR-guided boost (Type: EXPERIMENTAL): Patients will receive a dose of 36.25 Gy in 5 fractions to the entire prostate and proximal seminal vesicles with an additional boost to the dominant lesion for a total of 40 Gy in 5 fractions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy